Nintedanib in patients with progressive fibrosing ILDs in subgroups by comorbidity burden

被引：0
|
作者：
Bendstrup, E. [1 ]
Moua, T. [2 ]
Okamoto, M. [3 ]
Tomassetti, S. [4 ]
Valenzuela, C. [5 ]
Wuyts, A. [6 ]
Miede, C. [7 ]
Lievens, D. [8 ]
Bonella, F. [9 ]
机构：
[1] Aarhus Univ Hosp, Dept Resp Dis & Allergy, Ctr Rare Lung Dis, Aarhus, Denmark
[2] Mayo Clin Rochester, Div Pulm & Crit Care Med, Rochester, MN USA
[3] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan
[4] Careggi Univ Hosp, Dept Expt & Clin Med, Florence, Italy
[5] Univ Autonoma Madrid, Hosp Univ Princesa, Madrid, Spain
[6] Univ Hosp Leuven, Dept Pulm Med, Unit Interstitial Lung Dis, Leuven, Belgium
[7] Mainanalytics GmbH, Sulzbach, Taunus, Germany
[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[9] Univ Duisburg Essen, Pneumol Dept, Ctr Interstitial & Rare Lung Dis, Ruhrlandklin, Essen, Germany
来源：
EUROPEAN RESPIRATORY JOURNAL | 2022年 / 60卷
关键词：
D O I：
10.1183/13993003.congress-2022.615
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
    Wollin, Lutz
    Distler, Joerg H. W.
    Redente, Elizabeth F.
    Riches, David W. H.
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    Maher, Toby M.
    Kolb, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (03)
  • [42] Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
    Martin Kolb
    Kevin R. Flaherty
    Rafael S. Silva
    Antje Prasse
    Carlo Vancheri
    Heiko Mueller
    Kamila Sroka-Saidi
    Athol U. Wells
    Advances in Therapy, 2023, 40 : 5536 - 5546
  • [43] Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
    Kolb, Martin
    Flaherty, Kevin R.
    Silva, Rafael S.
    Prasse, Antje
    Vancheri, Carlo
    Mueller, Heiko
    Sroka-Saidi, Kamila
    Wells, Athol U.
    INBUILD Trial Investigators
    ADVANCES IN THERAPY, 2023, 40 (12) : 5536 - 5546
  • [44] Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?
    Behr, J.
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J. W.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R. G.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    PNEUMOLOGIE, 2021, 75 : S31 - S32
  • [45] Associations between neutrophil and lymphocyte counts and ILD progression in subjects with progressive fibrosing ILDs
    Kreuter, Michael
    Oldham, Justin M.
    Valenzuela, Claudia
    Suda, Takafumi
    Mueller, Heiko
    Sroka-Saidi, Kamila
    Maher, Toby M.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [46] Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [47] HEALTHCARE RESOURCE UTILIZATION AND RELATED COSTS IN PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS)
    Olson, A.
    Hartmann, N.
    Patnaik, P.
    Garry, E.
    Bohn, R.
    Singer, D.
    Baldwin, M.
    Wallace, L.
    VALUE IN HEALTH, 2020, 23 : S353 - S353
  • [48] SAFETY AND TOLERABILITY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES (ILDS) IN SUBGROUPS BY SEX AND AGE
    Hoffmann-Vold, A. M.
    Volkmann, E.
    Allanore, Y.
    Assassi, S.
    De Vries-Bouwstra, J.
    Smith, V.
    Tschoepe, I.
    Loaiza, L.
    Kanakapura, M.
    Distler, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 338 - 339
  • [49] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases
    Bonella, F.
    Matteson, E.
    Kelly, C.
    Distler, J. H. W.
    Hoffmann-Vold, A.
    Seibold, J. R.
    Mittoo, S.
    Distler, O.
    Goeldner, R. G.
    Schlenker-Herceg, R.
    Stowasser, S.
    Quaresma, M.
    Flaherty, K. R.
    PNEUMOLOGIE, 2020, 74 : S61 - S62
  • [50] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
    Matteson, Eric
    Kelly, Clive
    Distler, Joerg
    Mann-Vold, Anna Maria Hoff
    Seibold, James
    Mittoo, Shikha
    Distler, Oliver
    Goeldner, Rainer-Georg
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345